Ulrike Harjes
@ulrikeharjes.bsky.social
PhD, Senior editor for oncology at Nature Medicine @natmedicine.bsky.social. Previously at Nature Reviews Cancer. Views are my own.
Reposted by Ulrike Harjes
Now at #ESMO25: In the phase 2/3 AGITG DYNAMIC-III trial, post-surgery ctDNA was prognostic but de-escalated chemotherapy in patients with ctDNA-negative stage III colon cancer did not meet non-inferiority for 3 year recurrence-free survival https://www.nature.com/articles/s41591-025-04030-w
October 20, 2025 at 2:02 PM
Now at #ESMO25: In the phase 2/3 AGITG DYNAMIC-III trial, post-surgery ctDNA was prognostic but de-escalated chemotherapy in patients with ctDNA-negative stage III colon cancer did not meet non-inferiority for 3 year recurrence-free survival https://www.nature.com/articles/s41591-025-04030-w
Reposted by Ulrike Harjes
Now at #ESMO25: in the phase 3 RELATIVITY-098 trial, nivolumab + relatlimab did not significantly change recurrence free survival for patients with stage III/IV resected melanoma, and the absence of tumor infiltrating LAG3+ T cells may play a role. https://www.nature.com/articles/s41591-025-04032-8
October 18, 2025 at 7:00 AM
Now at #ESMO25: in the phase 3 RELATIVITY-098 trial, nivolumab + relatlimab did not significantly change recurrence free survival for patients with stage III/IV resected melanoma, and the absence of tumor infiltrating LAG3+ T cells may play a role. https://www.nature.com/articles/s41591-025-04032-8
Reposted by Ulrike Harjes
Now at #ESMO25: In the phase 2 IKF/AIO PHERFLOT trial, perioperative FLOT + anti-PD-1 + anti-HER2 led to a pathological complete response rate of 48.4% in patients with resectable HER2+ esophagogastric adenocarcinoma @JosephTintelnot https://www.nature.com/articles/s41591-025-03979-y
October 18, 2025 at 8:00 AM
Now at #ESMO25: In the phase 2 IKF/AIO PHERFLOT trial, perioperative FLOT + anti-PD-1 + anti-HER2 led to a pathological complete response rate of 48.4% in patients with resectable HER2+ esophagogastric adenocarcinoma @JosephTintelnot https://www.nature.com/articles/s41591-025-03979-y
Reposted by Ulrike Harjes
Now at #ESMO25: In a phase 2 trial, first-line treatment of patients with advanced gastric cancer, GEJ cancer or esophageal adenocarcinoma with anti-TIGIT + anti-PD-1 + FOLFOX led to encouraging objective response rates and survival outcomes https://www.nature.com/articles/s41591-025-04022-w
October 18, 2025 at 9:00 AM
Now at #ESMO25: In a phase 2 trial, first-line treatment of patients with advanced gastric cancer, GEJ cancer or esophageal adenocarcinoma with anti-TIGIT + anti-PD-1 + FOLFOX led to encouraging objective response rates and survival outcomes https://www.nature.com/articles/s41591-025-04022-w
Reposted by Ulrike Harjes
Now at #ESMO25: In patients with locally advanced or metastatic solid tumors, treatment with a first in class inhibitor of the Hippo-YAP-TEAD pathway was safe and led to encouraging clinical response rates in patients with mesothelioma https://www.nature.com/articles/s41591-025-04029-3
October 19, 2025 at 2:01 PM
Now at #ESMO25: In patients with locally advanced or metastatic solid tumors, treatment with a first in class inhibitor of the Hippo-YAP-TEAD pathway was safe and led to encouraging clinical response rates in patients with mesothelioma https://www.nature.com/articles/s41591-025-04029-3
"Antigen-presenting mast cells are new players in breast cancer immunotherapy" by #NachoMelero, a N&V on "Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial" by Shao et al, : www.nature.com/articles/s41... #Immunotherapy
Antigen-presenting mast cells are new players in breast cancer immunotherapy - Nature Medicine
A new study identifies a novel subset of mast cells that cross-present tumor antigens in patients triple-negative breast cancer — and a pilot clinical trial shows how these can be exploited in immunot...
www.nature.com
June 27, 2025 at 7:04 AM
"Antigen-presenting mast cells are new players in breast cancer immunotherapy" by #NachoMelero, a N&V on "Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial" by Shao et al, : www.nature.com/articles/s41... #Immunotherapy
Mobilizing antigen-presenting #MastCells in anti-PD-1-refractory triple-negative #BreastCancer: a phase 2 trial
by Song-Yang WuXi JinYi-Zhou Jiang #TNBC www.nature.com/articles/s41...
by Song-Yang WuXi JinYi-Zhou Jiang #TNBC www.nature.com/articles/s41...
Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial - Nature Medicine
In a reverse-translational study followed by a clinical trial, the targeting of antigen-presenting mast cells was identified as a therapeutic approach to overcome anti-PD-1 resistance in patients with...
www.nature.com
June 27, 2025 at 7:02 AM
Mobilizing antigen-presenting #MastCells in anti-PD-1-refractory triple-negative #BreastCancer: a phase 2 trial
by Song-Yang WuXi JinYi-Zhou Jiang #TNBC www.nature.com/articles/s41...
by Song-Yang WuXi JinYi-Zhou Jiang #TNBC www.nature.com/articles/s41...
To celebrate our 30th anniversary, Nature Medicine has commissioned 'Turning points' articles, in which researchers discuss the impact of their scientific discovery that was published around 30 yrs ago. Read this one: PD-L1 and the dawn of modern cancer immunotherapy www.nature.com/articles/s41...
PD-L1 and the dawn of modern cancer immunotherapy - Nature Medicine
Lieping Chen describes how his discoveries with PD-L1 yielded life-saving treatments for several cancers.
www.nature.com
May 5, 2025 at 11:26 AM
To celebrate our 30th anniversary, Nature Medicine has commissioned 'Turning points' articles, in which researchers discuss the impact of their scientific discovery that was published around 30 yrs ago. Read this one: PD-L1 and the dawn of modern cancer immunotherapy www.nature.com/articles/s41...
Reposted by Ulrike Harjes
After a boom in microbiome research over the past decade, the field’s next step is finding wider clinical applications for their results. Researchers explore how clinical microbiome research has evolved, the opportunities for the field and the challenges it faces in this review.
#medsky 🩺⚕️
#medsky 🩺⚕️
Clinical translation of microbiome research - Nature Medicine
This Review summarizes recent and compelling examples of microbiome-based interventions that are ripe for clinical adoption while also discussing the challenges and opportunities facing the field.
rdcu.be
May 5, 2025 at 10:10 AM
After a boom in microbiome research over the past decade, the field’s next step is finding wider clinical applications for their results. Researchers explore how clinical microbiome research has evolved, the opportunities for the field and the challenges it faces in this review.
#medsky 🩺⚕️
#medsky 🩺⚕️
Reposted by Ulrike Harjes
Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer - Nature Medicine
Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows that mol...
www.nature.com
March 19, 2025 at 2:34 AM
Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...
Reposted by Ulrike Harjes
🧵(1/2) NEW #NatureMedicine #immunotherapy trial -- led & conducted by #NIH researchers. It shows that neoantigen-specific tumor-infiltrating lymphocytes elicit responses in patients w/ treatment-refractory, MMR proficient #GI cancers #OncSky #MedSky www.nature.com/articles/s41...
Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial - Nature Medicine
In an iterative phase 2 trial, patients with metastatic, treatment-refractory, mismatch repair proficient gastrointestinal cancers had responses to neoantigen-reactive tumor-infiltrating lymphocytes b...
www.nature.com
April 1, 2025 at 6:31 PM
🧵(1/2) NEW #NatureMedicine #immunotherapy trial -- led & conducted by #NIH researchers. It shows that neoantigen-specific tumor-infiltrating lymphocytes elicit responses in patients w/ treatment-refractory, MMR proficient #GI cancers #OncSky #MedSky www.nature.com/articles/s41...
Reposted by Ulrike Harjes
Take Nature’s poll -
the new administration is reshaping the research landscape in the United States in profound ways.
What do you think of all the changes?
@nature.com
www.nature.com/articles/d41...
the new administration is reshaping the research landscape in the United States in profound ways.
What do you think of all the changes?
@nature.com
www.nature.com/articles/d41...
Take Nature’s poll: How will Trump’s policies affect US science?
The new administration is reshaping the research landscape in the United States in profound ways. What do you think of all the changes?
www.nature.com
April 4, 2025 at 7:26 AM
Take Nature’s poll -
the new administration is reshaping the research landscape in the United States in profound ways.
What do you think of all the changes?
@nature.com
www.nature.com/articles/d41...
the new administration is reshaping the research landscape in the United States in profound ways.
What do you think of all the changes?
@nature.com
www.nature.com/articles/d41...
Reposted by Ulrike Harjes
Find all Springer Nature journal and imprint accounts on Bluesky ⬇️.
January 29, 2025 at 10:43 AM
Find all Springer Nature journal and imprint accounts on Bluesky ⬇️.
Reposted by Ulrike Harjes
Quadruplets induction regimens are the established standards of care now in newly diagnosed MM, just out 🎉👇🏽
#MyelomaSky
@mskcancercenter.bsky.social
@imfmyeloma.bsky.social
@themmrf.bsky.social
@healthtreeorg.bsky.social
www.nature.com/articles/s41...
#MyelomaSky
@mskcancercenter.bsky.social
@imfmyeloma.bsky.social
@themmrf.bsky.social
@healthtreeorg.bsky.social
www.nature.com/articles/s41...
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study - Nature Medicine
In the phase 3 CEPHEUS trial, patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma were treated with subcutaneous daratumumab plus bortezomib, lenalidomide and d...
www.nature.com
February 6, 2025 at 12:00 PM
Quadruplets induction regimens are the established standards of care now in newly diagnosed MM, just out 🎉👇🏽
#MyelomaSky
@mskcancercenter.bsky.social
@imfmyeloma.bsky.social
@themmrf.bsky.social
@healthtreeorg.bsky.social
www.nature.com/articles/s41...
#MyelomaSky
@mskcancercenter.bsky.social
@imfmyeloma.bsky.social
@themmrf.bsky.social
@healthtreeorg.bsky.social
www.nature.com/articles/s41...
New out in #NatureMedicine: In the ph 3 #CEPHEUS trial, #daratumumab + bortezomib, lenalidomide & dexamethasone (D-VRd) in transplant-ineligible or transplant-deferred newly diagnosed #MultipleMyeloma showed deeper & more durable increase in #MRD responses vs VRd. www.nature.com/articles/s41...
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study - Nature Medicine
In the phase 3 CEPHEUS trial, patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma were treated with subcutaneous daratumumab plus bortezomib, lenalidomide and d...
www.nature.com
February 6, 2025 at 10:45 AM
New out in #NatureMedicine: In the ph 3 #CEPHEUS trial, #daratumumab + bortezomib, lenalidomide & dexamethasone (D-VRd) in transplant-ineligible or transplant-deferred newly diagnosed #MultipleMyeloma showed deeper & more durable increase in #MRD responses vs VRd. www.nature.com/articles/s41...
Reposted by Ulrike Harjes
A study in Nature confirms that the phenomenon of mitochondrial transfer can occur bidirectionally between cytotoxic T cells and cancer cells within the tumour microenvironment. This leads to senescence of the T cells and impaired antitumour immunity.
www.nature.com/articles/s41... 🧪
www.nature.com/articles/s41... 🧪
Immune evasion through mitochondrial transfer in the tumour microenvironment - Nature
Mitochondria with mutations in their DNA from cancer cells can be transferred to T cells in the tumour microenvironment, which leads to T cell dysfunction and impaired antitumour immunity.
www.nature.com
January 27, 2025 at 1:29 PM
A study in Nature confirms that the phenomenon of mitochondrial transfer can occur bidirectionally between cytotoxic T cells and cancer cells within the tumour microenvironment. This leads to senescence of the T cells and impaired antitumour immunity.
www.nature.com/articles/s41... 🧪
www.nature.com/articles/s41... 🧪
New out in #NatureMedicine & at #ASCOGI: In the practice-changing #BREAKWATER ph3 trial, encorafenib, cetuximab & mFOLFOX6 vs investigator’s choice of CT w/wo bev in BRAF V600E mCRC led to improved ORR, w/ PFS still maturing.
Congrats to @skopetz.bsky.social et al!
www.nature.com/articles/s41...
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial - Nature Medicine
As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic colorectal cancer received the BRAF inhibitor encorafenib,...
www.nature.com
January 27, 2025 at 7:31 AM
New out in #NatureMedicine & at #ASCOGI: In the practice-changing #BREAKWATER ph3 trial, encorafenib, cetuximab & mFOLFOX6 vs investigator’s choice of CT w/wo bev in BRAF V600E mCRC led to improved ORR, w/ PFS still maturing.
Congrats to @skopetz.bsky.social et al!
www.nature.com/articles/s41...
New out in #NatureMedicine: A phase 1 trial shows that the size of #CTC clusters (which can promote metastatic spread) can be reduced by treatment with the Na+/K+ ATPase inhibitor #digoxin in patients with metastatic #BreastCancer. By Nicola Aceto et al.
www.nature.com/articles/s41...
Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial - Nature Medicine
This proof-of-concept phase 1 trial shows that the size of circulating tumor cell clusters (which can promote metastatic spread) can be reduced by treatment with the Na+/K+ ATPase inhibitor digoxin in...
www.nature.com
January 24, 2025 at 3:24 PM
New out in #NatureMedicine: A phase 1 trial shows that the size of #CTC clusters (which can promote metastatic spread) can be reduced by treatment with the Na+/K+ ATPase inhibitor #digoxin in patients with metastatic #BreastCancer. By Nicola Aceto et al.
www.nature.com/articles/s41...
Reposted by Ulrike Harjes
The research community has flocked to the social-media platform Bluesky.
Tell us about your experience
https://go.nature.com/42fihQG
Tell us about your experience
https://go.nature.com/42fihQG
Has Bluesky replaced X for scientists? Take Nature’s poll
The research community has flocked to the social-media platform Bluesky. Tell us about your experience.
go.nature.com
January 14, 2025 at 4:56 PM
The research community has flocked to the social-media platform Bluesky.
Tell us about your experience
https://go.nature.com/42fihQG
Tell us about your experience
https://go.nature.com/42fihQG
Reposted by Ulrike Harjes
Overview of molecular characteristics of pancreatic cancer from @mskcancercenter.bsky.social @mskdeptofmed.bsky.social with useful data. Reminder that KRAS is 95% of pancreatic cancer (~1% G12C), 10% have germline pathogenic alterations (e.g. BRCA1/2, ATM, PALB2). www.nature.com/articles/s41...
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival - Nature Medicine
Analyses of clinical and genomic data from a cohort of 2,336 patients with pancreatic adenocarcinoma find that KRAS dosage gains are a hallmark of disease progression and are predictive of poor outcom...
www.nature.com
January 6, 2025 at 2:06 PM
Overview of molecular characteristics of pancreatic cancer from @mskcancercenter.bsky.social @mskdeptofmed.bsky.social with useful data. Reminder that KRAS is 95% of pancreatic cancer (~1% G12C), 10% have germline pathogenic alterations (e.g. BRCA1/2, ATM, PALB2). www.nature.com/articles/s41...
Reposted by Ulrike Harjes
Using multiple data sets, a machine learning model using routine blood and clinical data is shown to be predictive of patient response to immune checkpoint inhibitor therapy, across cancer types and outperforming standard biomarkers
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data - Nature Medicine
Using multiple datasets from real-world evidence and completed trials, a machine learning model using routine blood and clinical data is shown to be predictive of patient response to immune checkpoint...
www.nature.com
January 7, 2025 at 2:06 PM
Using multiple data sets, a machine learning model using routine blood and clinical data is shown to be predictive of patient response to immune checkpoint inhibitor therapy, across cancer types and outperforming standard biomarkers
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Ulrike Harjes
🌟 NEW in #NatureMedicine: Repeat infusions of B7-H3 #CARTcells were safe in children with diffuse intrinsic pontine glioma (#DIPG). Median OS = 19.8 months vs historical OS = 11 months. 3 patients alive 40 months post-diagnosis! @nickvitanza.bsky.social #OncSky www.nature.com/articles/s41...
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial - Nature Medicine
In the final report of a phase 1 trial evaluating intracerebroventricular B7-H3-targeting CAR T cells in children and young adults with diffuse intrinsic pontine glioma, repeated intracranial infusion...
www.nature.com
January 7, 2025 at 1:24 PM
🌟 NEW in #NatureMedicine: Repeat infusions of B7-H3 #CARTcells were safe in children with diffuse intrinsic pontine glioma (#DIPG). Median OS = 19.8 months vs historical OS = 11 months. 3 patients alive 40 months post-diagnosis! @nickvitanza.bsky.social #OncSky www.nature.com/articles/s41...
New out in #NatureMedicine @natureportfolio.bsky.social :
Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations
by Qi Long & Ravi B. Parikh et al
#MachineLearning #Oncology
www.nature.com/articles/s41...
Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations
by Qi Long & Ravi B. Parikh et al
#MachineLearning #Oncology
www.nature.com/articles/s41...
Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations - Nature Medicine
Machine-learning-based and population-level electronic health record data–based emulation of landmark phase 3 randomized controlled trials (RCTs) in oncology across a range of cancer and risk types sh...
www.nature.com
January 6, 2025 at 7:19 AM
New out in #NatureMedicine @natureportfolio.bsky.social :
Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations
by Qi Long & Ravi B. Parikh et al
#MachineLearning #Oncology
www.nature.com/articles/s41...
Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations
by Qi Long & Ravi B. Parikh et al
#MachineLearning #Oncology
www.nature.com/articles/s41...
Reposted by Ulrike Harjes
What trials will shape medicine in 2025?
@oncodaily.bsky.social @cancertrialsie.bsky.social
@natureportfolio.bsky.social has the answer.
Great to feature a trial on radionuclides featuring as well a number of other cancer related studies
www.nature.com/articles/s41...
@oncodaily.bsky.social @cancertrialsie.bsky.social
@natureportfolio.bsky.social has the answer.
Great to feature a trial on radionuclides featuring as well a number of other cancer related studies
www.nature.com/articles/s41...
Eleven clinical trials that will shape medicine in 2025 - Nature Medicine
Nature Medicine asks leading researchers to name their top clinical trial for 2025, from gene therapies for prion disease and sickle-cell disease to digital tools for cancer and mental health.
www.nature.com
December 13, 2024 at 5:03 PM
What trials will shape medicine in 2025?
@oncodaily.bsky.social @cancertrialsie.bsky.social
@natureportfolio.bsky.social has the answer.
Great to feature a trial on radionuclides featuring as well a number of other cancer related studies
www.nature.com/articles/s41...
@oncodaily.bsky.social @cancertrialsie.bsky.social
@natureportfolio.bsky.social has the answer.
Great to feature a trial on radionuclides featuring as well a number of other cancer related studies
www.nature.com/articles/s41...
very cool study in Nature by @colindascheele.bsky.social from VIB-CCB, Leuven
The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy - Nature
In three mouse models of breast cancer, we show reduced responses to neoadjuvant chemotherapy when treatment is initiated during the dioestrus stage, when compared with initiation during the oestrus s...
www.nature.com
December 10, 2024 at 5:45 PM
very cool study in Nature by @colindascheele.bsky.social from VIB-CCB, Leuven